Other languages Qualigen Therapeutics, Inc.

Equities

QLGN

US74754R2022

Market Closed - Nasdaq Other stock markets 02:00:00 09/05/2024 am IST			5-day change	1st Jan Change
0.2802 ^USD	-1.65%		-6.51%	-49.05%

16/04	Marizyme Enters into Co-Development Agreement with Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft?	CI
08/04	Qualigen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Marizyme Enters into Co-Development Agreement with Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft?	16/04
Qualigen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/04
Qualigen Therapeutics, Inc. Enters into A Termination Agreement with Pan-RAS Holdings, Inc	29/03
Qualigen Therapeutics, Inc. Enters into A License and Sublicense Agreement with Pan-RAS Holdings, Inc	23/02
Qualigen Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
Qualigen Therapeutics, Inc. Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors	07/11
Qualigen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15
Qualigen Therapeutics Announces UD FDA IND Clearance to Initiate Phase 1 Clinical Trial of Qn-302 for Treatment of Advanced or Metastatic Solid Tumors	01/23/01
Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. for $5.8 million.	24/23/24
Biosynex : acquisition de Qualigen aux Etats-Unis	21/23/21
Qualigen Therapeutics, Inc. Announces Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and Director	27/23/27
Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology 2023 Annual Meeting	05/23/05
Qualigen Therapeutics, Inc. Announces the Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and A Director, Effective June 16, 2023	19/23/19
Qualigen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16
Qualigen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	03/23/03
Qualigen Therapeutics Receives Nasdaq's Non-Compliance Notice	24/23/24
Qualigen Therapeutics Says QN-302 US Patent Granted; Shares Rise	21/23/21
Qualigen Therapeutics, Inc. to Present Five Posters At the American Association for Cancer Research Annual Meeting 2023	15/23/15
Qualigen Therapeutics, Inc. Announces Publication of Key Data in the Peer-Reviewed Journal Molecules	08/23/08
Qualigen Therapeutics, Inc. Initiates Good Laboratory Practice Toxicology Studies on QN-302	24/23/24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Qualigen Therapeutics, Inc.

Equities

QLGN

US74754R2022

Other languages

Filters